Using cost-effectiveness analysis to support policy change: varenicline and nicotine replacement therapy for smoking cessation in Jordan

Table 2 Life years gained and medication costs incurred per treatment arm and age group

	Cost (in JDs)	Life years	Number intending to quit	Cycles
Age 30–34
Varenicline	33,043,140	2,829,590	123,476	40
NRT	23,497,344	2,815,827	123,476	40
Brief counseling	2,570,022	2,797,447	123,476	40
Age 35–39
Varenicline	29,199,690	2,013,904	109,453	35
NRT	20,764,224	2,004,786	109,453	35
Brief counseling	2,271,087	1,986,592	109,453	35
Age 40–44
Varenicline	24997680	1330153	95,062	30
NRT	17776128	1321244	95,062	30
Brief counseling	1944264	1306761	95,062	30
Age 45–49
Varenicline	20,887,200	825,156	80,768	25
NRT	14,853,120	820,792	80,768	25
Brief counseling	1,624,560	812,682	80,768	25
Age 50–54
Varenicline	14668560	408252	59,340	20
NRT	10430976	405324	59,340	20
Brief counseling	1140888	402227	59,340	20
Age 55–59
Varenicline	9,338,760	182,218	40,366	15
NRT	6,640,896	181,688	40,366	15
Brief counseling	726,348	180,711	40,366	15
Age 60–64
Varenicline	2,271,510	32,060	10,883	10
NRT	1,615,296	31,897	10,883	10
Brief counseling	176,613	31,363	10,883	10
Age 65–70
Varenicline	1,342,170	13,045	7770	5
NRT	954,432	12,880	7770	5
Brief counseling	104,391	12,625	7770	5
Total
Varenicline	135,748,710	7,625,378	527,118	180
NRT	96,532,416	7,594,438	527,118	180
Brief counseling	10,558,173	7,530,408	527,118	180

ISSN: 2052-3211